KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Treasury Shares: 2018-2024

Historic Treasury Shares for Amneal Pharmaceuticals (AMRX) over the last 1 years, with Dec 2024 value amounting to $17.6 million.

  • Amneal Pharmaceuticals' Treasury Shares rose 0.70% to $17.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $17.6 million, marking a year-over-year increase of 0.70%. This contributed to the annual value of $17.6 million for FY2024, which is 0.70% up from last year.
  • Amneal Pharmaceuticals' Treasury Shares amounted to $17.6 million in Q4 2024, which was up 0.70% from $17.5 million recorded in Q4 2023.
  • Amneal Pharmaceuticals' Treasury Shares' 5-year high stood at $17.9 million during Q4 2022, with a 5-year trough of $9.1 million in Q4 2020.
  • Over the past 3 years, Amneal Pharmaceuticals' median Treasury Shares value was $17.6 million (recorded in 2024), while the average stood at $17.7 million.
  • In the last 5 years, Amneal Pharmaceuticals' Treasury Shares soared by 246.28% in 2020 and then fell by 2.64% in 2023.
  • Quarterly analysis of 4 years shows Amneal Pharmaceuticals' Treasury Shares stood at $9.1 million in 2020, then reached $17.9 million in 2022, then declined by 2.64% to $17.5 million in 2023, then increased by 0.70% to $17.6 million in 2024.
  • Its Treasury Shares was $17.6 million in Q4 2024, compared to $17.5 million in Q4 2023 and $17.9 million in Q4 2022.